TherapeuticsMD, Inc.
TXMD Healthcare Drug Manufacturers Specialty & Generic
TherapeuticsMD, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.0 million, up 71.6% from fiscal 2024. In the quarter to June 2026, revenue fell 8.72%, EPS fell 80.0% and free cash flow grew 104.5%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow TXMD
TherapeuticsMD, Inc. (TXMD) EV/Sales
As of 16 October 2026, TherapeuticsMD, Inc. (TXMD) trades at a EV/Sales of 85.1×. Over the past ten years it has ranged from −30.6× (April 2022) to 284× (August 2024); the current reading is higher than 75% of that period. That is above the Drug Manufacturers Specialty & Generic industry median of 2.7× and above the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | 91.6× | (40.32%) |
| FY2024 | 153× | (29.99%) |
| FY2023 | 219× | 5,527.74% |
| FY2022 | 3.9× | (97.71%) |
| FY2021 | 170× | 2,141.92% |
| FY2020 | 7.6× | (40.25%) |
| FY2019 | 12.7× | (73.38%) |
| FY2018 | 47.8× | (30.99%) |
| FY2017 | 69.2× | 28.96% |
| FY2016 | 53.7× | (37.54%) |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | 86.2× | 3.06% |
| Mar 2026 | 83.6× | (8.70%) |
| Dec 2025 | 91.6× | (5.43%) |
| Sep 2025 | 96.8× | (9.14%) |
| 42 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| IXHL Incannex Healthcare Inc. compare | −19.9× |
| UPC Universe Pharmaceuticals INC compare | −0.2× |
| SHPH Shuttle Pharmaceuticals Holdings, Inc. compare | n/m |
| BGXXQ Bright Green Corporation compare | n/m |
| RMTI Rockwell Medical, Inc. compare | 0.2× |
| AYTU Aytu BioPharma, Inc. compare | 0.3× |
| SCYX SCYNEXIS, Inc. compare | 0.7× |
| CPHI China Pharma Holdings, Inc. compare | 8.1× |
| TXMD TherapeuticsMD, Inc. | 85.1× |
| Drug Manufacturers Specialty & Generic industry median | 2.7× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)